The National Center for Complementary and Integrative Health states that "research doesn't clearly support using cinnamon for ...

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced ...

Linerixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, improved cholestatic pruritus in patients ...

Distinct trends were seen in etiology-based mortality with chronic liver disease (CLD) before, during, and after the COVID-19 ...

How alcohol affects women differently than men from metabolism and liver damage to cancer risk mental health and hormonal ...

I’m a pediatrician in metabolic diseases, and every day in my clinical work I’m confronted with our lack in effective therapies for our patients.” That was the sobering introduction by Sabine Fuchs in ...

GSK plc (NYSE:GSK) met the main goal in a late-stage trial of linerixibat, a treatment for cholestatic pruritus, a severe ...

The FDA approved ustekinumab-aekn (Selarsdi) injection as an interchangeable biosimilar to Stelara for the treatment of Crohn ...

European Region has the heaviest alcohol consumption of all regions in the world, causing a significant reduction in life expectancy, especially among men. Approximately 800,000 lives are lost each ...

An experimental new treatment is showing early promise in the fight against liver fibrosis—a serious and often silent condition that affects around 2 million people in the UK.

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in ...

Liver disease patients are falling through the cracks and not getting the treatment they need. Support from people with lived experience of disease could bridge the gap.